Sarepta Therapeutics | SRPT - Interest Expense On Debt


Sarepta Therapeutics reported $7.56M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Capricor Therapeutics 581K 581K Dec/2024
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Gilead Sciences USD 255M 1000K Dec/2025
Incyte USD 582K 10K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Tectonic Therapeutic USD 277M 276.98M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025